Rocque, Mariève J.
Leipart, Vilde
Kumar Singh, Ashish
Mur, Pilar
Olsen, Maren F.
Engebretsen, Lars F.
Martin-Ramos, Edgar
Aligué, Rosa
Sætrom, Pål
Valle, Laura
Drabløs, Finn
Otterlei, Marit
Sjursen, Wenche http://orcid.org/0000-0003-3880-6440
Funding for this research was provided by:
Helse Midt-Norge (90278800)
European Cooperation in Science and Technology (COST Action CA17118, COST Action CA17118)
St. Olavs Hospital Universitetssykehuset i Trondheim (16/9564-98/NISLIN)
FEDER funds- a way to build Europe (SAF2016-80888-R)
Instituto de Salud Carlos III (CIBERONC CB16/12/00234)
NTNU Norwegian University of Science and Technology
Article History
Received: 16 March 2022
Accepted: 15 February 2023
First Online: 1 March 2023
Declarations
:
: The authors declare no conflict of interest.
: The Mid-Norway regional committees for medical and health research ethics has approved the project (REK#14805). The mutation carriers whose tumors were analyzed with whole-exome sequencing (WES) gave written informed consent for participation and publication.